PE20191478A1 - Compuestos moduladores del receptor de hidorcarburos de arilo (ahr) - Google Patents

Compuestos moduladores del receptor de hidorcarburos de arilo (ahr)

Info

Publication number
PE20191478A1
PE20191478A1 PE2019001482A PE2019001482A PE20191478A1 PE 20191478 A1 PE20191478 A1 PE 20191478A1 PE 2019001482 A PE2019001482 A PE 2019001482A PE 2019001482 A PE2019001482 A PE 2019001482A PE 20191478 A1 PE20191478 A1 PE 20191478A1
Authority
PE
Peru
Prior art keywords
ahr
hydrocarbon receptor
aryl hydrocarbon
modulating compounds
compounds
Prior art date
Application number
PE2019001482A
Other languages
English (en)
Inventor
Christoph Steeneck
Ulrich Deuschle
Michael Albers
Thomas Hoffmann
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of PE20191478A1 publication Critical patent/PE20191478A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a compuestos derivados de pirrolopiridina de formula (I), donde A y B son arilo (mono o biciclico) de 6 a 10 miembros o heteroarilo (mono o biciclico) de 5 a 10 miembros, opcionalmente sustituidos con OH, halogeno, CN alquilo C1-C6, entre otros; R1, R2 y R3 son H, halogeno, alquilo C1-C3, entre otros; Rb es h o alquilo C1-C6. Dichos compuestos son moduladores del receptor de hidrocarburos de arilo (AhR) y son utiles en el tratamiento y/o profilaxis de enfermedades y/o condiciones a traves de la union de dicho receptor del hidrocarburo de arilo por dichos compuestos
PE2019001482A 2017-02-01 2018-02-01 Compuestos moduladores del receptor de hidorcarburos de arilo (ahr) PE20191478A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17000158 2017-02-01
PCT/EP2018/052542 WO2018141857A1 (en) 2017-02-01 2018-02-01 Aryl hydrocarbon receptor (ahr) modulator compounds

Publications (1)

Publication Number Publication Date
PE20191478A1 true PE20191478A1 (es) 2019-10-16

Family

ID=57960223

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001482A PE20191478A1 (es) 2017-02-01 2018-02-01 Compuestos moduladores del receptor de hidorcarburos de arilo (ahr)

Country Status (28)

Country Link
US (1) US10981908B2 (es)
EP (1) EP3577112B1 (es)
JP (1) JP6849823B2 (es)
KR (1) KR102320516B1 (es)
CN (1) CN110248940B (es)
AR (1) AR110789A1 (es)
AU (1) AU2018216957B2 (es)
BR (1) BR112019015716A2 (es)
CA (1) CA3050827C (es)
CL (1) CL2019002108A1 (es)
CO (1) CO2019007881A2 (es)
CR (1) CR20190392A (es)
CU (1) CU20190069A7 (es)
EA (1) EA038318B1 (es)
EC (1) ECSP19055169A (es)
ES (1) ES2858329T3 (es)
IL (1) IL268080B (es)
MX (1) MX2019008994A (es)
MY (1) MY196831A (es)
NI (1) NI201900076A (es)
PE (1) PE20191478A1 (es)
PH (1) PH12019550135A1 (es)
SG (1) SG11201906958TA (es)
TW (1) TWI752155B (es)
UA (1) UA122745C2 (es)
UY (1) UY37589A (es)
WO (1) WO2018141857A1 (es)
ZA (1) ZA201904771B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) * 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
FI3749669T3 (fi) 2018-02-06 2023-05-26 Ideaya Biosciences Inc AHR-modulaattoreita
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
AU2019387491A1 (en) * 2018-11-30 2021-05-27 Celularity Inc. Expansion of natural killer cells and ILC3 cells with novel aromatic compounds
US20230108408A1 (en) * 2020-01-23 2023-04-06 Phenex Pharmaceuticals Ag Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
WO2021173082A1 (en) 2020-02-26 2021-09-02 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of ahr signalling
US20230234967A1 (en) * 2020-05-28 2023-07-27 Senda Biosciences, Inc. Fused Azole Heterocycles as AHR Antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
CN115572282A (zh) * 2021-07-05 2023-01-06 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8225991A (en) 1990-07-31 1992-03-02 Teikoku Hormone Mfg. Co., Ltd. 2-phenylindole derivative
JP2001506980A (ja) 1996-11-19 2001-05-29 アムジエン・インコーポレーテツド アリールおよびヘテロアリール置換縮合ピロール抗炎症剤
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
DE602006017741D1 (de) 2005-11-18 2010-12-02 Hoffmann La Roche Azaindol-2-carboxamid-derivate
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
AU2010307006B2 (en) 2009-10-13 2016-08-11 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
US20130338201A1 (en) * 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
JP5598775B2 (ja) * 2009-11-02 2014-10-01 ソン,ジャシェン 癌の介入治療および根絶のためのiteとその類似体を含む医薬組成物
ES2445917T3 (es) 2010-02-03 2014-03-06 Takeda Pharmaceutical Company Limited Inhibidores de quinasa 1 reguladora de la señal de apoptosis
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US10314810B2 (en) 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
JP2015534957A (ja) 2012-10-17 2015-12-07 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Trpチャネル拮抗薬としての6−アミノインドール誘導体
UY35240A (es) 2012-12-21 2014-07-31 Plexxikon Inc Compuestos y métodos para la modulación de quinasas y sus indicaciones
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物

Also Published As

Publication number Publication date
EP3577112A1 (en) 2019-12-11
ES2858329T3 (es) 2021-09-30
CA3050827C (en) 2021-09-07
US10981908B2 (en) 2021-04-20
CN110248940A (zh) 2019-09-17
NZ755709A (en) 2021-04-30
JP6849823B2 (ja) 2021-03-31
WO2018141857A1 (en) 2018-08-09
CU20190069A7 (es) 2020-03-04
KR102320516B1 (ko) 2021-11-02
ECSP19055169A (es) 2019-08-30
IL268080A (en) 2019-09-26
MY196831A (en) 2023-05-03
CR20190392A (es) 2019-10-21
AR110789A1 (es) 2019-05-02
AU2018216957A1 (en) 2019-08-22
SG11201906958TA (en) 2019-08-27
CL2019002108A1 (es) 2019-12-20
UA122745C2 (uk) 2020-12-28
EA038318B1 (ru) 2021-08-09
US20190389857A1 (en) 2019-12-26
AU2018216957B2 (en) 2020-09-24
JP2020506228A (ja) 2020-02-27
NI201900076A (es) 2020-01-23
UY37589A (es) 2018-02-28
EP3577112B1 (en) 2020-12-30
CO2019007881A2 (es) 2019-10-09
EA201991599A1 (ru) 2020-03-10
CA3050827A1 (en) 2018-08-09
TWI752155B (zh) 2022-01-11
ZA201904771B (en) 2022-05-25
MX2019008994A (es) 2019-12-19
PH12019550135A1 (en) 2020-06-01
CN110248940B (zh) 2022-07-01
KR20190104410A (ko) 2019-09-09
IL268080B (en) 2022-03-01
TW201831480A (zh) 2018-09-01
BR112019015716A2 (pt) 2020-03-24

Similar Documents

Publication Publication Date Title
PE20191478A1 (es) Compuestos moduladores del receptor de hidorcarburos de arilo (ahr)
PE20191479A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
EA201991598A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АРИЛУГЛЕВОДОРОДНЫЙ РЕЦЕПТОР (AhR)
PE20180117A1 (es) Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
PE20171623A1 (es) Agentes inmunomoduladores
UY36838A (es) Compuestos heterocíclicos moduladores de la señalización de tnf alfa y composiciones farmacéuticas que los contienen
PE20200292A1 (es) Compuestos de heteroarilo biciclicos 6-6 fusionados y su uso como inhibidores de lats
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
UY37169A (es) Análogos de 1,4-dihidropirimidin-5-carboxamidas como agonistas de apj y composiciones que los contienen
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
PE20161366A1 (es) Heterociclil-sulfonas sustituidas con heteroarilo
CO2021006672A2 (es) Moduladores de nlrp3
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
EA201270778A1 (ru) Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
PE20170120A1 (es) Compuestos novedosos de pirimidina sustituidos
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
PE20160860A1 (es) Derivados de etinil-imidazolidin-2,4-diona como moduladores de mglur 4
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
EA202092444A1 (ru) Тризамещенные арильные и гетероарильные производные как модуляторы киназы pi3 и путей аутофагии